DANIEL KINSEY: Open Payments
NPI 1306880109 · GOSHEN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,993 in 23 payments from 10 companies in 2025. Trend: 2023 $74 · 2024 $990 · 2025 $1,993
Food & beverage: $1,882Education: $111
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $303 |
| Alkermes, Inc. | 3 | $282 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $281 |
| Axsome Therapeutics, Inc. | 3 | $233 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $205 |
| Corium, LLC | 2 | $203 |
| Teva Pharmaceuticals USA, Inc. | 2 | $183 |
| E.R. Squibb & Sons, L.L.C. | 2 | $155 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $94 |
| ABBVIE INC. | 1 | $56 |
Products named: INGREZZA, ARISTADA, CAPLYTA, Azstarys, COBENFY, REJOYN, Auvelity, AUSTEDO XR.
Industry payments across IN — which companies pay providers there.
